A multicentre, comparative study of Cera septal occluder versus AMPLATZER Septal Occluder in transcatheter closure of secundum atrial septal defects

Basit Öğe Kaydı
dc.contributor.authorKaya, Mehmet Gungor
dc.contributor.authorAkpek, Mahmut
dc.contributor.authorCelebi, Ahmet
dc.contributor.authorSaritas, Turkay
dc.contributor.authorMeric, Murat
dc.contributor.authorSoylu, Korhan
dc.contributor.authorKarapinar, Hekim
dc.contributor.authorLam, Yat-Yin
dc.date.accessioned2019-07-27T12:10:23Z
dc.date.accessioned2019-07-28T09:56:59Z
dc.date.available2019-07-27T12:10:23Z
dc.date.available2019-07-28T09:56:59Z
dc.date.issued2014
dc.department[Kaya, Mehmet Gungor -- Akpek, Mahmut] Erciyes Univ, Sch Med, Dept Cardiol, Kayseri, Turkey -- [Celebi, Ahmet -- Saritas, Turkay] Dr Siyami Ersek Thorac & Cardiovasc Surg Ctr, Dept Pediat Cardiol, Istanbul, Turkey -- [Meric, Murat] Ondokuz Mayis Univ, Dept Cardiol, Sch Med, Samsun, Turkey -- [Soylu, Korhan -- Karapinar, Hekim] Cumhuriyet Univ, Sch Med, Dept Cardiol, Sivas, Turkey -- [Lam, Yat-Yin] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Div Cardiol, Hong Kong, Hong Kong, Peoples R Chinaen_US
dc.description.abstractAims: To evaluate the safety and efficacy of the new Cera septal occluder (CSO) for atrial septal defect (ASD) closure as compared to the AMPLATZER Septal Occluder (ASO). Methods and results: A total of 405 ASD patients receiving CSO or ASO were studied. The ASDs were classified into simple defects (isolated defects <26 mm) or complex defects (isolated defects >26 mm, large defects with a deficient rim, double or multi-fenestrated defects). Clinical and echocardiographic findings were collected before discharge, at one month, and every six months after implantation. Two hundred and five (133 females, aged 30 +/- 13 years) and 200 (135 females, aged 28 +/- 14 years) patients received CSO and ASO implants, respectively. The CSO group had similar ASD and device sizes, prevalence of complex lesions, procedural times and success rates as compared to the ASO group. Echocardiographic follow-up at one and six months showed similar residual shunts between devices. Both groups had similar rates for device embolisation and atrial arrhythmia. The average equipment cost per patient was lower in the CSO group than in the ASO group (US$3,500 vs. US$5,600, p<0.001). Conclusions: Transcatheter ASD closure with CSO is safe and effective. It appears to be an attractive alternative to ASO because of its relatively low cost.en_US
dc.identifier.doi10.4244/EIJY14M07_04en_US
dc.identifier.endpage631en_US
dc.identifier.issn1774-024X
dc.identifier.issn1969-6213
dc.identifier.issue5en_US
dc.identifier.pmid25022224en_US
dc.identifier.scopus2-s2.0-84907485075en_US
dc.identifier.scopusqualityQ1
dc.identifier.startpage626en_US
dc.identifier.urihttps://dx.doi.org/10.4244/EIJY14M07_04
dc.identifier.urihttps://hdl.handle.net/20.500.12418/8188
dc.identifier.volume10en_US
dc.identifier.wosWOS:000343956500017en_US
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherEUROPA EDITIONen_US
dc.relation.ispartofEUROINTERVENTIONen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCera septal occluderen_US
dc.subjectsecundum atrial septal defecten_US
dc.subjecttranscatheter closureen_US
dc.titleA multicentre, comparative study of Cera septal occluder versus AMPLATZER Septal Occluder in transcatheter closure of secundum atrial septal defectsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu